CARISOPRODOL
Active substance: carisoprodol
TABLET · CARISOPRODOL 350 mg/1
United StatesActive
Marketing holder: ScieGen Pharmaceuticals, Inc.
Verified 2026-10-09 · openFDA NDC
- Source: openFDA NDC
- Countries with the substance registered: 1
Composition
- CARISOPRODOL · 350 mg/1
Import and control
Control by country
- United StatescontrolledSchedule: CIV
Source: openFDA NDC · record 01a1208c-2966-7b09-8680-1f8541135872,01a1208c-2d08-7433-85b9-b68be323a20e,01a1208c-348f-7148-bb60-b7ffb0a99611,01a1208c-4a8a-78a2-9611-0de110eb6bc2,01a1208c-5b14-72de-b1a4-1068145d5046;count=54 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 50228-109
- Registration status
- Active
- Dispensing
- Prescription only
- Control marker
- CIV
- Route
- ORAL
Sources
- product · openFDA NDC · 50228-109 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 50228-109 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 50228-109 · Verified 2026-10-09 · open in source